![]() Perlmutter will then work with Amgen as a consultant to aid in the transition until February, 2013. Roger Perlmutter, 59, will retire as executive vice president of research and development effective February 12, 2012. Bradway holds a BA in Biology from Amherst College and an MBA from Harvard University. Prior to joining Amgen, Bradway worked for 19 years with Morgan Stanley. He was appointed CFO in 2007, and was named president and chief operating officer in 2010. Under his tenure Amgen grew from $3.6B in revenue with a presence in 17 countries to a company today with revenues approaching $16B and operations in 55 countries.īob Bradway, 48, joined Amgen in 2006 as a vice president in operations. Sharer, 63, joined Amgen in 1992 and served as president until 2000 when he was named chairman and CEO. In the months ahead, we will focus on making the transition to Bob and Sean seamless." He has been an outstanding head of research and development, and his accomplishments have benefited millions of patients. I would particularly like to thank Roger Perlmutter for his eleven years of service. "Bob and Sean have demonstrated sound judgment, delivered consistently excellent operating results and provided strong leadership in a variety of challenging roles. "Today Amgen announces its next generation of leaders as we pass the reins to Bob Bradway and Sean Harper," said Kevin Sharer. ![]() The Board is excited to have a talented executive in Bob Bradway as the fourth CEO in our Company's history." Amgen's core mission to serve patients remains our bedrock. During that time Amgen grew significantly in every dimension and is well positioned for the future. On behalf of the Board of Directors, Vance Coffman, chairman of the Board's governance and nominating committee said, "The Board thanks Kevin Sharer for his service in leading Amgen over the past decade. The Board will also elect a lead independent director at that time. It is the intention of the Board of Directors to elect Bradway chairman of the Board when Sharer retires from that position at the end of 2012. Robert Bradway, currently president and chief operating officer, will become CEO on May 23, 2012. To facilitate an orderly transition process, Sharer will step down as CEO effective May 23, 2012, and remain as chairman of the Company's Board of Directors until December 31, 2012, at which time he will retire from the Board and from the Company. Sharer, chairman and chief executive officer of Amgen (NASDAQ:AMGN) since 2000, has announced his plan to retire from the Company at the end of 2012, following 20 years of service to Amgen. Clinical Trial Diversity and RepresentationĬlinical Trial Transparency, Data Sharing and Disclosure PracticesĪdverse Event and Product Complaint ReportingĮnvironmental, Social & Governance Report 2021Įnvironment, Social and Governance StrategyĬommunity Investment and Amgen Foundation
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |